Stability of Ceftazidime Pentahydrate Investigated by Thermal Analysis Techniques

Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing Escherichia coli

Escherichia coli has been associated with the induction of colorectal cancer (CRC). Thus, combined therapy incorporating usnic acid (UA) and antibiotics such as ceftazidime (CAZ), co-encapsulated in liposomes, could be an alternative. Coating the liposomes with chitosan (Chi) could facilitate the oral administration of this nanocarrier. Liposomes were prepared using the lipid film hydration method, followed by sonication and chitosan coating via the drip technique. Characterization included particle size, polydispersity index, zeta potential, pH, encapsulation efficiency, and physicochemical analyses. The minimum inhibitory concentration and minimum bactericidal concentration were determined against E. coli ATCC 25922, NCTC 13846, and H10407 using the microdilution method. Antibiofilm assays were conducted using the crystal violet method. The liposomes exhibited sizes ranging from 116.5 ± 5.3 to 240.3 ± 3.5 nm and zeta potentials between +16.4 ± 0.6 and +28 ± 0.8 mV. The encapsulation efficiencies were 51.5 ± 0.2% for CAZ and 99.94 ± 0.1% for UA. Lipo-CAZ-Chi and Lipo-UA-Chi exhibited antibacterial activity, inhibited biofilm formation, and preformed biofilms of E. coli. The Lipo-CAZ-UA-Chi and Lipo-CAZ-Chi + Lipo-UA-Chi formulations showed enhanced activities, potentially due to co-encapsulation or combination effects. These findings suggest potential for in vivo oral administration in future antibacterial and antibiofilm therapies against CRC-inducing bacteria.

Effect of intrauterine infusion of two cephalosporins, ceftazidime and cephapirin, on uterine bacterial load and uterine horn diameter in bovine subclinical endometritis

This study aimed to evaluate the effect of intrauterine infusion of ceftazidime and cephapirin on uteri­ne bacterial load and uterine horn diameter in bovine subclinical endometritis. At 7-8 weeks postpartum, a total of 122 cows suffering from subclinical endometritis were divided into three groups. Group I cows were intrauterinely (IU) infused with 2 g ceftazidime diluted with 50 mL saline; group II cows were IU infused with 2 g cephapirin diluted with 50 mL saline; and group III cows were kept as untreated control. Vaginal examination, ultrasonography and bacterial examination were done before treatment programme and later repeated twice at 10-day intervals. Staphylococcus spp., Klebsiella spp., Streptococcus spp., Escherichia coli and Proteus spp. were isolated. After the end of the treatment programme, proportions of cows infected with Staphylococcus spp. and Streptococcus spp. were significantly (P<0.05) decreased in ceftazidime and cephapirin groups. However, proportions of cows infected with Escherichia coli were significantly (P<0.05) decreased in the ceftazidime group only. Uterine bacterial loads in ceftazidime and cephapirin groups were significantly decreased (P<0.05). Mean uterine horn diameters in ceftazidime group (2.44±0.03 cm) became significantly lower (P<0.05) than those in cephapirin (2.70±0.04 cm) and control (3.06±0.06 cm) groups. Conception rate in ceftazidime group (80.95%) was significantly (P<0.05) higher than rates recorded in cephapirin (64.00%) and control (26.67%) groups. In conclusion, ceftazidime and cephapirin decreased uterine bacterial load. Moreover, ceftazidime significantly reduced uterine horn diameter compared to the other groups and was associated with significantly higher conception rate. Thus, ceftazidime is recommended for treatment of subclinical endometritis in dairy cows.